ReviewCardiovascular therapeutics2020
The Role of Clopidogrel in 2020: A Reappraisal.
Review in Cardiovascular therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 114 citations in OpenAlex.
- The Role of Genetics in Stroke Risk and Outcome: A Review of Current Evidence.Brain and behavior · 2025Pooled it
- Impact of CYP2C19 point-of-care testing on the clinical outcome in patients receiving personalized clopidogrel therapy: systemic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- β-Ketoamides in Thieno[2,3-Molecules (Basel, Switzerland) · 2026Article
- Article
- Clinical outcomes of a generic versus brand-name clopidogrel for secondary prevention in patients with ischemic stroke: a nationwide retrospective cohort study.BMC neurology · 2026Article
- Haemostasis and the Need for Antithrombotics: An Introduction.Handbook of experimental pharmacology · 2026Review
- P2YBiomedicines · 2025Article
- A QSPR study of coronary artery disease drugs using eccentricity-based indices.Scientific reports · 2025Article
- A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications.NPJ genomic medicine · 2025Review
- Association of P2RY12 Gene Variants and Non-Genetic Factors With Clopidogrel Responsiveness in Vietnamese Patients After Percutaneous Coronary Intervention: A Cross-Sectional Study.Journal of clinical laboratory analysis · 2025Article
- Does Adenosine Triphosphate via Purinergic Receptor Signalling Fuel Pulmonary Fibrosis?Journal of innate immunity · 2025Review
- Antithrombotic Therapy Strategies and Clinical Outcomes in Chinese Patients Aged 65 and Older with High Ischemic Risk Coronary Artery Disease.Clinical interventions in aging · 2025Article
- Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled.BMC medical genomics · 2024Article
- The Effect of Formulation Variables on the Manufacturability of Clopidogrel Tablets via Fluidized Hot-Melt Granulation-From the Lab Scale to the Pilot Scale.Pharmaceutics · 2024Article
- Personalization of clopidogrel therapy based on genetic polymorphism analysis: clinical implications.American journal of translational research · 2024Article
- The Diversity ofThe application of clinical genetics · 2024Article
- Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.CPT: pharmacometrics & systems pharmacology · 2024Article
- The safety and effectiveness of clopidogrel versus aspirin in Kawasaki disease with mild-to-moderate liver injury.Scientific reports · 2023Article
- Aspirin and clopidogrel resistance; a neglected gap in stroke and cardiovascular practice in Iran: a systematic review and meta-analysis.Thrombosis journal · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiplatelet therapy is the mainstay of treatment and secondary prevention of cardiovascular disease (CVD), including acute coronary syndrome (ACS), transient ischemic attack (TIA) or minor stroke, and peripheral artery disease (PAD). The P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.